Tema Oncology ETF (NASDAQ:CANC) Short Interest Update

Tema Oncology ETF (NASDAQ:CANC) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 7,400 shares, a growth of 13.8% from the December 15th total of 6,500 shares. Based on an average trading volume of 11,800 shares, the short-interest ratio is currently 0.6 days.

Tema Oncology ETF Trading Down 0.1 %

Shares of NASDAQ:CANC opened at $24.46 on Friday. The firm has a market cap of $52.83 million, a price-to-earnings ratio of 26.86 and a beta of 1.11. The stock’s 50-day moving average price is $25.87 and its two-hundred day moving average price is $27.63. Tema Oncology ETF has a 12-month low of $23.97 and a 12-month high of $30.11.

Tema Oncology ETF Dividend Announcement

The company also recently disclosed a dividend, which was paid on Thursday, December 12th. Stockholders of record on Wednesday, December 11th were issued a $0.7283 dividend. The ex-dividend date was Wednesday, December 11th.

Institutional Trading of Tema Oncology ETF

An institutional investor recently bought a new position in Tema Oncology ETF stock. Thrivent Financial for Lutherans bought a new position in Tema Oncology ETF (NASDAQ:CANC) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 319,376 shares of the company’s stock, valued at approximately $8,616,000. Thrivent Financial for Lutherans owned 19.01% of Tema Oncology ETF at the end of the most recent reporting period.

Tema Oncology ETF Company Profile

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.